Moleculin Biotech, Inc. 8-K Report: Key Developments on December 18, 2024

Based on the provided section of the financial report, here are the key pieces of information extracted:

1. Company Information:

• Name: Moleculin Biotech, Inc.
• Incorporation State: Delaware (DE)
• CIK: 0001659617
• Address: 5300 Memorial Drive, Suite 950, Houston, TX 77007
• Phone Number: 713-300-5160

2. SEC Filing Details:

• Filing Type: 8-K
• Filing Date: December 18, 2024
• SEC File Number: 001-37758

3. Stock Information:

• Common Stock Ticker Symbol: MBRX
• Exchange: NASDAQ

4. Reporting Period:

• Start Date: December 18, 2024
• End Date: December 18, 2024
• The context indicates that this is a specific date reporting rather than a traditional reporting period (e.g., quarterly or annual).

5. Namespace Information:

• The document is structured in XBRL (eXtensible Business Reporting Language), indicating it is likely intended for automated financial analysis and reporting.

Insights:

• The filing is a Form 8-K, which typically indicates significant events or changes that shareholders should know about. The specific date suggests that this report may relate to a notable event that occurred on that day.
• The entity is listed on NASDAQ, which may help investors and analysts gauge market activity and stock performance.
• The concise nature of the reporting period (same start and end date) suggests that this filing may be addressing a specific corporate event rather than routine financial disclosures.

This information can be useful for investors, analysts, and stakeholders interested in recent developments related to Moleculin Biotech, Inc.